Genelux (GNLX) Amortizatization of Intangibles (2022 - 2026)
Genelux (GNLX) recorded quarterly Amortizatization of Intangibles of $89000.0 in Q1 2026, up 187.1% quarter-over-quarter from $31000.0 in Q3 2025, and down 36.43% on a YoY basis from $140000.0 in Q1 2025.
Genelux (GNLX) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Genelux's Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $89000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 36.43% year-over-year to $89000.0; the TTM figure through Mar 2026 stood at $277000.0 (down 60.2% YoY), while the FY2023 annual figure was $62000.0, down 75.97% from the prior year.
- Amortizatization of Intangibles was $89000.0 for Q1 2026 at Genelux, up from $31000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $649000.0 in Q1 2023 to a low of -$587000.0 in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $91916.7 across 5 years, with a median of $99500.0 in 2022.
- Biggest YoY gain for Amortizatization of Intangibles was 1224.49% in 2023; the steepest drop was 633.64% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $110000.0 in 2022, then tumbled by 633.64% to -$587000.0 in 2023, then surged by 142.93% to $252000.0 in 2024, then plunged by 87.7% to $31000.0 in 2025, then surged by 187.1% to $89000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $89000.0 (Q1 2026), $31000.0 (Q3 2025), and $17000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Dec 31, 2023 | -587,000.00 |
| Dec 31, 2023 | -587,000.00 |
| Mar 31, 2023 | 649,000.00 |
| Mar 31, 2023 | 649,000.00 |
| Dec 31, 2022 | 110,000.00 |
| Dec 31, 2022 | 110,000.00 |